Latest news
EYPT: Q2 2026 revenue fell 90% and net loss rose 59% as R&D spending surged for DURAVYU trials - TradingViewTradingView · Wed, 05 Aug 2026 20:07:27 GMTEyePoint Completes Enrollment in Two Phase 3 Trials Evaluating Duravyu for DME - Eyewire+Eyewire+ · Wed, 05 Aug 2026 18:46:05 GMTEYPT: DURAVYU advances as a potential first-in-class, long-acting TKI for major retinal diseases - TradingViewTradingView · Tue, 04 Aug 2026 11:21:19 GMTTopline DURAVYU Phase 3 data for DME expected in late 2027 as Eyepoint Pharmaceuticals advances studies - Traders UnionTraders Union · Fri, 31 Jul 2026 22:36:22 GMTEyePoint Completes Enrollment in Phase 3 Duravyu Trials for DME Ahead of Schedule - Eyewire+Eyewire+ · Fri, 31 Jul 2026 13:07:27 GMTEyePoint Completes Enrollment of DURAVYU Phase 3 Trials for Diabetic Macular Edema - The Clinical Trial VanguardThe Clinical Trial Vanguard · Fri, 31 Jul 2026 07:37:59 GMTEyePoint completes enrollments in Duravyu trials (EYPT:NASDAQ) - Seeking AlphaSeeking Alpha · Thu, 30 Jul 2026 17:52:57 GMTEyePoint Completes Early Enrollment of Phase 3 DURAVYU Trials for Diabetic Macular Edema, Topline Data Expected Q4 2027 – Minichart - MinichartMinichart · Thu, 30 Jul 2026 13:52:00 GMT